Prednisolone RPG may be available in the countries listed below.
Prednisolone 21-(sodium 3-sulfobenzoate) (a derivative of Prednisolone) is reported as an ingredient of Prednisolone RPG in the following countries:
International Drug Name Search
Butalbital and acetaminophen is supplied in tablet form for oral administration.
Butalbital (5-allyl-5-isobutylbarbituric acid), a slightly bitter, white, odorless, crystalline powder, is a short to intermediate-acting barbiturate. It has the following structural formula:
C11H16N2O3 MW = 224.26
Acetaminophen (4’-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:
C8H9NO2 MW = 151.17
Each Butapap tablet contains:
Butalbital …………………………………………….50 mg
Warning: May be habit forming.
Acetaminophen ……………………………………...650 mg
In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, pregelatinized starch, stearic acid with FD&C Blue #1 Lake as coloring.
This combination drug product is intended as a treatment for tension headache.
It consists of a fixed combination of butalbital and acetaminophen. The role each component plays in the relief of the complex of symptoms known as tension headache is incompletely understood.
The behavior of the individual components is described below.
Butalbital: Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.
Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products include parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-l-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% is conjugated.
The in vitro plasma protein binding of butalbital is 45% over the concentration range of 0.5 to 20 mcg/mL. This falls within the range of plasma protein binding (20% to 45%) reported with other barbiturates such as phenobarbital, pentobarbital, and secobarbital sodium. The plasma-to-blood concentration ratio was almost unity indicating that there is no preferential; distribution of butalbital into either plasma or blood cells (See OVERDOSAGE for toxicity information.).
Acetaminophen: Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug (See OVERDOSAGE for toxicity information.).
Butalbital and Acetaminophen Tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.
Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.
This product is contraindicated under the following conditions:
Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.
Butalbital and Acetaminophen Tablets should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.
This product may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.
Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.
Butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.
In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.
The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
Butalbital and acetaminophen may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.
No adequate studies have been conducted in animals to determine whether acetaminophen or butalbital have a potential for carcinogenesis, mutagenesis or impairment of fertility.
Animal reproduction studies have not been conducted with this combination product. It is also not known whether butalbital and acetaminophen can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only when clearly needed.
Withdrawal seizures were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last two months of pregnancy. Butalbital was found in the infant’s serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further seizure or other withdrawal symptoms.
Barbiturates and acetaminophen are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from butalbital and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients below the age of 12 have not been established.
Frequently Observed: The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling.
Infrequently Observed: All adverse events tabulated below are classified as infrequent.
Central Nervous System: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, sluggishness, seizure. Mental confusion, excitement or depression can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdosage of butalbital.
Autonomic Nervous System: dry mouth, hyperhidrosis.
Gastrointestinal: difficulty swallowing, heartburn, flatulence, constipation.
Cardiovascular: tachycardia.
Musculoskeletal: leg pain, muscle fatigue.
Genitourinary: diuresis.
Miscellaneous: pruritus, fever, earache, nasal congestion, tinnitus, euphoria, allergic reactions.
Several cases of dermatological reactions, including toxic epidermal necrolysis and erythema multiforme, have been reported.
The following adverse drug events may be borne in mind as a potential effect of the components of this product. Potential effects of high dosage are listed in the OVERDOSAGE section.
Acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.
Butalbital: Barbiturates may be habit-forming: Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.
Following an acute overdosage of butalbital and acetaminophen, toxicity may result from the barbiturate or the acetaminophen.
Toxicity from barbiturate poisoning includes drowsiness, confusion, and coma; respiratory depression; hypotension; and hypovolemic shock.
In acetaminophen overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necroses, hypoglycemic coma and thrombocytopenia may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams, or fatalities with less than 15 grams.
A single or multiple overdose with this combination product is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended.
Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced mechanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) should follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required. Hypotension is usually hypovolemic and should respond to fluids. Pressors should be avoided. A cuffed endotracheal tube should be inserted before gastric lavage of the unconscious patient and, when necessary, to provide assisted respiration. If renal function is normal, forced diuresis may aid in the elimination of the barbiturate. Alkalinization of the urine increases renal excretion of some barbiturates, especially phenobarbital.
Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of intoxication, peritoneal dialysis, or preferably hemodialysis may be considered. If hypoprothrombinemia occurs due to acetaminophen overdose, vitamin K should be administered intravenously.
If the dose of acetaminophen may have exceeded 140 mg/kg, acetylcysteine should be administered as early as possible. Serum acetaminophen levels should be obtained, since levels four or more hours following ingestion help predict acetaminophen toxicity. Do not await acetaminophen assay results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24-hour intervals.
Methemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration.
Toxic Doses (for adults):
Butalbital: toxic dose 1 g (20 tablets)
Acetaminophen: toxic dose 10 g (15 tablets)
Oral: One tablet every four hours. Total daily dosage should not exceed 6 tablets.
Extended and repeated use of this product is not recommended because of the potential for physical dependence.
Butapap Tablets (Butalbital and Acetaminophen Tablets) 50 mg/650 mg are supplied in bottles of 100 tablets, NDC 46672-098-10, and in bottles of 500 tablets, NDC 46672-098-50. Each tablet contains butalbital 50 mg (Warning: May be habit forming) and acetaminophen 650 mg. Tablets are uncoated, blue, capsule-shaped and are debossed “MIA/l12” on the same side as the single-score.
Storage: Protect from light and moisture. Store at controlled room temperature, 15°C to 30°C (59°F to 86°F).
Dispense in a tight, light-resistant container with a child-resistant closure.
Rx only
Manufactured by:
MIKART, INC.
Atlanta, GA 30318
Rev. 05/00 Code 612Z00
| BUTALBITAL AND ACETAMINOPHEN butalbital and acetaminophen tablet | ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
Supplementing the diet to treat or prevent vitamin deficiency. It may also be used for other conditions as determined by your doctor.
Rx Support Heartburn and Acid Reflux is a vitamin combination. It works by increasing the amounts of folic acid, vitamins B6 and B12, vitamin D, and calcium in the body.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Rx Support Heartburn and Acid Reflux. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Rx Support Heartburn and Acid Reflux. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Rx Support Heartburn and Acid Reflux may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Rx Support Heartburn and Acid Reflux as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Rx Support Heartburn and Acid Reflux.
All medicines may cause side effects, but many people have no, or minor side effects. No COMMON side effects have been reported with this product. Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty grasping with your hands; difficulty walking; itching, tingling, or numbness of fingers or toes; loss of muscle coordination.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Rx Support Heartburn and Acid Reflux side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Rx Support Heartburn and Acid Reflux at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Rx Support Heartburn and Acid Reflux out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Rx Support Heartburn and Acid Reflux. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Asasurfan may be available in the countries listed below.
Sulfasalazine is reported as an ingredient of Asasurfan in the following countries:
International Drug Name Search
Actal may be available in the countries listed below.
Alexitol Sodium is reported as an ingredient of Actal in the following countries:
Aluminium Hydroxide is reported as an ingredient of Actal in the following countries:
Aluminium Hydroxide hydrate (Algeldrate) (a derivative of Aluminium Hydroxide) is reported as an ingredient of Actal in the following countries:
Simeticone is reported as an ingredient of Actal in the following countries:
International Drug Name Search
VESIcare is a brand name of solifenacin, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of VESIcare available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of VESIcare. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Solinfec may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Solinfec in the following countries:
International Drug Name Search
Acetil colina intraocular may be available in the countries listed below.
Acetylcholine Chloride is reported as an ingredient of Acetil colina intraocular in the following countries:
International Drug Name Search
Fenemal may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Phenobarbital is reported as an ingredient of Fenemal in the following countries:
International Drug Name Search
Penicillin V Stada may be available in the countries listed below.
Phenoxymethylpenicillin potassium (a derivative of Phenoxymethylpenicillin) is reported as an ingredient of Penicillin V Stada in the following countries:
International Drug Name Search
Generic Name: biperiden (bye PEAR i den)
Brand Names: Akineton HCl
Biperiden reduces the effects of certain naturally occurring chemicals in your body that may become unbalanced as a result of disease (such as Parkinson's disease), drug therapy, or other causes.
Biperiden is used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease. It is also used to treat and prevent these same muscular conditions when they are caused by drugs such as chlorpromazine (Thorazine), fluphenazine (Prolixin), perphenazine (Trilafon), and others.
Biperiden may also be used for purposes other than those listed in this medication guide.
Avoid becoming overheated. Biperiden may cause decreased sweating. This could lead to heat stroke in hot weather or with vigorous exercise.
have ever had an allergic reaction to it,
have narrow-angle glaucoma,
have an obstruction in your bowel or a complication of bowel disease known as megacolon; or
have myasthenia gravis.
Before taking this medication, tell your doctor if you have
an enlarged prostate or difficulty urinating,
epilepsy or another seizure disorder,
heart disease or an irregular heartbeat,
depression or any other psychiatric illness, or
You may need a lower dose or special monitoring during treatment if you have any of the conditions listed above.
Take biperiden exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse or doctor to explain them to you.
Biperiden may be taken once or several times a day. The maximum amount of biperiden that should be taken in any one day is eight tablets (16 mg). Follow your doctor's instructions.
See also: Biperiden dosage (in more detail)
Take the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and only take your next regularly scheduled dose. Do not take a double dose of this medication.
Symptoms of a biperiden overdose include large pupils; warm, dry skin; flushed face; fever; dry mouth; fast or irregular heartbeat; anxiety; hallucinations; confusion; agitation; hyperactivity; loss of consciousness; and seizures.
Avoid becoming overheated. Biperiden may cause decreased sweating. This could lead to heat stroke in hot weather or with vigorous exercise. Try to keep as cool as possible and watch for signs of heat stroke such as decreased sweating, nausea, and dizziness.
an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
unusual fever;
fast or irregular heartbeat;
anxiety, hallucinations, confusion, agitation, hyperactivity, or loss of consciousness;
seizures;
a rash; or
eye pain.
Other, less serious side effects may be more likely to occur. Continue to take biperiden and talk to your doctor if you experience
a dry mouth;
large pupils or blurred vision;
drowsiness;
difficulty urinating or constipation;
nervousness or anxiety;
upset stomach; or
decreased sweating.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Parkinson's Disease:
2 mg orally 3 to 4 times a day; the dose may be titrated up to a maximum of 16 mg per 24 hours
Usual Adult Dose for Extrapyramidal Reaction:
Neuroleptic-induced: 2 mg orally 1 to 3 times a day
Before taking this medication, tell your doctor if you are taking:
a phenothiazine (used to treat mania, schizophrenia, other psychiatric conditions, and nausea and vomiting) such as chlorpromazine (Thorazine), fluphenazine (Prolixin), perphenazine (Trilafon), mesoridazine (Serentil), thioridazine (Mellaril), promazine (Sparine), trifluoperazine (Stelazine), and others;
an antihistamine such as diphenhydramine (Benadryl, others), chlorpheniramine (Chlor-Trimeton, others), triprolidine (Actifed, others), brompheniramine (Dimetapp, others), clemastine (Tavist) and others (antihistamines are often found in prescription and over-the-counter cold, allergy, and sleep medicines);
quinidine (Quinora, Quinaglute, Quinidex, Cardioquin);
amantadine (Symmetrel);
digoxin (Lanoxin, Lanoxicaps); or
haloperidol (Haldol).
Drugs other than those listed here may also interact with biperiden. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
See also: biperiden side effects (in more detail)
Lipolar may be available in the countries listed below.
Bromopride is reported as an ingredient of Lipolar in the following countries:
International Drug Name Search
Gnostocardin may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Gnostocardin in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
L01BB03
0000154-42-7
C5-H5-N5-S
167
Antineoplastic agent, antimetabolite
6H-Purine-6-thione, 2-amino-1,7-dihydro-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Ambene may be available in the countries listed below.
Phenylbutazone is reported as an ingredient of Ambene in the following countries:
Phenylbutazone sodium salt (a derivative of Phenylbutazone) is reported as an ingredient of Ambene in the following countries:
International Drug Name Search
Generic Name: pyrithione (Topical route)
pir-i-THYE-one
In the U.S.
Available Dosage Forms:
Therapeutic Class: Dermatological Agent
Chemical Class: Pyrethrums
Pyrithione is used to help control the symptoms of dandruff and seborrheic dermatitis of the scalp.
This medicine is available without a prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Although there is no specific information comparing use of pyrithione in children with use in other age groups, this medicine is not expected to cause different side effects or problems in children than it does in adults.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing use of pyrithione in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
This section provides information on the proper use of a number of products that contain pyrithione. It may not be specific to DermaZinc. Please read with care.
For best results, use this medicine at least 2 times a week or as directed by your doctor.
To use:
Keep this medicine away from the eyes. If you should accidentally get some in your eyes, flush them thoroughly with water.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
If your condition does not get better after regular use of this medicine, or if it gets worse, check with your doctor.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: DermaZinc Topical side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
In some countries, this medicine may only be approved for veterinary use.
Chloramphenicol is reported as an ingredient of Chlorasol in the following countries:
International Drug Name Search
Oxitocina Aps may be available in the countries listed below.
Oxytocin is reported as an ingredient of Oxitocina Aps in the following countries:
International Drug Name Search
Chinidinum Sulfuricum may be available in the countries listed below.
Quinidine sulfate (a derivative of Quinidine) is reported as an ingredient of Chinidinum Sulfuricum in the following countries:
International Drug Name Search
Roximisan may be available in the countries listed below.
Roxithromycin is reported as an ingredient of Roximisan in the following countries:
International Drug Name Search
Bumetanide A may be available in the countries listed below.
Bumetanide is reported as an ingredient of Bumetanide A in the following countries:
International Drug Name Search
Cimetidin-CT may be available in the countries listed below.
Cimetidine is reported as an ingredient of Cimetidin-CT in the following countries:
Cimetidine hydrochloride (a derivative of Cimetidine) is reported as an ingredient of Cimetidin-CT in the following countries:
International Drug Name Search
Sanpilo may be available in the countries listed below.
Pilocarpine hydrochloride (a derivative of Pilocarpine) is reported as an ingredient of Sanpilo in the following countries:
International Drug Name Search
Cital may be available in the countries listed below.
Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Cital in the following countries:
International Drug Name Search
Lamotrigin Copyfarm may be available in the countries listed below.
Lamotrigine is reported as an ingredient of Lamotrigin Copyfarm in the following countries:
International Drug Name Search
Telebrix may be available in the countries listed below.
Ioxitalamic Acid meglumine (a derivative of Ioxitalamic Acid) is reported as an ingredient of Telebrix in the following countries:
Ioxitalamic Acid meglumine and sodium salt (a derivative of Ioxitalamic Acid) is reported as an ingredient of Telebrix in the following countries:
International Drug Name Search
Pyoben may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Benzoyl Peroxide is reported as an ingredient of Pyoben in the following countries:
International Drug Name Search
In the US, Zoladex (goserelin systemic) is a member of the following drug classes: gonadotropin releasing hormones, hormones/antineoplastics and is used to treat Bleeding Disorder, Breast Cancer - Palliative, Endometriosis and Prostate Cancer.
US matches:
UK matches:
Goserelin is reported as an ingredient of Zoladex in the following countries:
Goserelin acetate (a derivative of Goserelin) is reported as an ingredient of Zoladex in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Tiaprid Hexal may be available in the countries listed below.
Tiapride hydrochloride (a derivative of Tiapride) is reported as an ingredient of Tiaprid Hexal in the following countries:
International Drug Name Search
Norifaz may be available in the countries listed below.
Risedronic Acid monosodium (a derivative of Risedronic Acid) is reported as an ingredient of Norifaz in the following countries:
International Drug Name Search
Phenylbutazone Molex Ayus may be available in the countries listed below.
Phenylbutazone is reported as an ingredient of Phenylbutazone Molex Ayus in the following countries:
International Drug Name Search
Proloc may be available in the countries listed below.
Pantoprazole is reported as an ingredient of Proloc in the following countries:
International Drug Name Search
Bricanyl Turbohaler may be available in the countries listed below.
UK matches:
Terbutaline sulfate (a derivative of Terbutaline) is reported as an ingredient of Bricanyl Turbohaler in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Cyproteronacetat dura may be available in the countries listed below.
Cyproterone 17α-acetate (a derivative of Cyproterone) is reported as an ingredient of Cyproteronacetat dura in the following countries:
International Drug Name Search
Alexan may be available in the countries listed below.
Cytarabine is reported as an ingredient of Alexan in the following countries:
Spironolactone is reported as an ingredient of Alexan in the following countries:
International Drug Name Search
Kancin Gap may be available in the countries listed below.
Amikacin sulfate (a derivative of Amikacin) is reported as an ingredient of Kancin Gap in the following countries:
International Drug Name Search
Prazosin Atid may be available in the countries listed below.
Prazosin hydrochloride (a derivative of Prazosin) is reported as an ingredient of Prazosin Atid in the following countries:
International Drug Name Search
Apaurin may be available in the countries listed below.
Diazepam is reported as an ingredient of Apaurin in the following countries:
International Drug Name Search
ratio-Amcinonide may be available in the countries listed below.
Amcinonide is reported as an ingredient of ratio-Amcinonide in the following countries:
International Drug Name Search
Nocazin may be available in the countries listed below.
Isoconazole nitrate (a derivative of Isoconazole) is reported as an ingredient of Nocazin in the following countries:
International Drug Name Search
Melatonina Quiarsa may be available in the countries listed below.
Melatonin is reported as an ingredient of Melatonina Quiarsa in the following countries:
International Drug Name Search
Atovarol may be available in the countries listed below.
Atorvastatin is reported as an ingredient of Atovarol in the following countries:
Atorvastatin calcium (a derivative of Atorvastatin) is reported as an ingredient of Atovarol in the following countries:
International Drug Name Search
Histam may be available in the countries listed below.
Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Histam in the following countries:
International Drug Name Search
Valerpan may be available in the countries listed below.
Betamethasone 17α,21-dipropionate and 21-(disodium phosphate) (a derivative of Betamethasone) is reported as an ingredient of Valerpan in the following countries:
International Drug Name Search
Metoprolol-Z AL may be available in the countries listed below.
Metoprolol tartrate (a derivative of Metoprolol) is reported as an ingredient of Metoprolol-Z AL in the following countries:
International Drug Name Search
Sertralin ratiopharm may be available in the countries listed below.
Sertraline is reported as an ingredient of Sertralin ratiopharm in the following countries:
Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertralin ratiopharm in the following countries:
International Drug Name Search
Atropine Sulphate Atlantic may be available in the countries listed below.
Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Atropine Sulphate Atlantic in the following countries:
International Drug Name Search
Bleomycinesulfaat PCH may be available in the countries listed below.
Bleomycin sulfate (a derivative of Bleomycin) is reported as an ingredient of Bleomycinesulfaat PCH in the following countries:
International Drug Name Search
Metoclopramide EG may be available in the countries listed below.
Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Metoclopramide EG in the following countries:
International Drug Name Search
Solozorin may be available in the countries listed below.
Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Solozorin in the following countries:
International Drug Name Search
Sanigermin may be available in the countries listed below.
Triclosan is reported as an ingredient of Sanigermin in the following countries:
International Drug Name Search
Quamatel may be available in the countries listed below.
Famotidine is reported as an ingredient of Quamatel in the following countries:
International Drug Name Search
Tamsulosina Alter may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Alter in the following countries:
International Drug Name Search
Lotriderm may be available in the countries listed below.
Betamethasone 17α,21-dipropionate (a derivative of Betamethasone) is reported as an ingredient of Lotriderm in the following countries:
Clotrimazole is reported as an ingredient of Lotriderm in the following countries:
International Drug Name Search
Flutide Evohaler may be available in the countries listed below.
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Flutide Evohaler in the following countries:
International Drug Name Search
Raltiva may be available in the countries listed below.
Fexofenadine is reported as an ingredient of Raltiva in the following countries:
International Drug Name Search
See also: Generic Glucophage XR
Glucophage is a brand name of metformin, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Glucophage:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Glucophage. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Glucophage.
